Pemafibrate, a novel selective PPARα modulator, attenuates tamoxifen-induced fatty liver disease
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Journal of Gastroenterology"
DOI: 10.1007/s12328-021-01386-7
Abstract: Estrogen receptor (ER) antagonists, such as tamoxifen and toremifene, are widely used as adjuvant therapies for ER-positive breast cancer. These agents sometimes cause hepatosteatosis and steatohepatitis and it is problematic whether these agents should be… read more here.
Keywords: ppar; liver disease; pemafibrate; fatty liver ... See more keywords
Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-06542-8
Abstract: Although patients with nonalcoholic fatty liver disease have been reported to have cardiac dysfunction, and appropriate model has not been reported. We established a novel mouse model of diet-induced steatohepatitis-related cardiomyopathy and evaluated the effect… read more here.
Keywords: steatohepatitis related; related cardiomyopathy; heart; pemafibrate ... See more keywords
Pemafibrate protects the rupture of experimental aortic aneurysm in mice through anti-oxidative stress with induced catalase
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3789
Abstract: Abdominal aortic aneurysm (AAA) is a life-threatening disease, while effective and preventive medical treatments remain unestablished. The aim of this study was to evaluate the effect of selective peroxi- some proliferator-activated receptor alpha (PPARα) modulator… read more here.
Keywords: treated mice; pemafibrate; mice; catalase ... See more keywords
Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study
Sign Up to like & getrecommendations! Published in 2020 at "Hepatology Research"
DOI: 10.1111/hepr.13571
Abstract: Dyslipidemia (DL) is commonly associated with non‐alcoholic fatty liver disease (NAFLD). Pemafibrate, a selective peroxisome proliferator activated receptor α modulator (SPPARMα), has been shown to improve liver function among patients with DL. The aim of… read more here.
Keywords: alcoholic fatty; fatty liver; non alcoholic; liver ... See more keywords
Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-01172-8
Abstract: Background Currently available treatments have only been partly successful in patients with severe hypertriglyceridemia, including those with high serum triglycerides above 1,000 mg/dL (11.3 mmol/L), who often suffer from acute pancreatitis. Pemafibrate is a novel selective peroxisome… read more here.
Keywords: mmol; severe hypertriglyceridemia; selective peroxisome; pemafibrate ... See more keywords
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes care"
DOI: 10.2337/dc21-1288
Abstract: OBJECTIVE High plasma triglyceride (TG) is an independent risk factor for cardiovascular disease. Fibrates lower TG levels through peroxisome proliferator-activated receptor α (PPARα) agonism. Currently available fibrates, however, have relatively low selectivity for PPARα. The… read more here.
Keywords: ppar; pemafibrate selective; ppar modulator; 877 pemafibrate ... See more keywords
Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10112806
Abstract: Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD… read more here.
Keywords: htg nafld; fat mass; pemafibrate; responsiveness women ... See more keywords
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
Sign Up to like & getrecommendations! Published in 2023 at "Metabolites"
DOI: 10.3390/metabo13050626
Abstract: Statins, the intestinal cholesterol transporter inhibitor (ezetimibe), and PCSK9 inhibitors can reduce serum LDL-C levels, leading to a significant reduction in cardiovascular events. However, these events cannot be fully prevented even when maintaining very low… read more here.
Keywords: ppar modulator; nonalcoholic fatty; pemafibrate; fatty liver ... See more keywords
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Atherosclerosis and Thrombosis"
DOI: 10.5551/jat.44412
Abstract: Aim: To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety… read more here.
Keywords: 200 day; safety; day day; pemafibrate ... See more keywords
Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Atherosclerosis and Thrombosis"
DOI: 10.5551/jat.63659
Abstract: Aim: Pemafibrate is a highly selective agonist for peroxisome proliferator-activated receptor (PPAR)-α, a key regulator of lipid and glucose metabolism. We compared the efficacy and safety of pemafibrate with those of bezafibrate, a nonselective PPAR-α… read more here.
Keywords: pemafibrate; safety pemafibrate; randomized crossover; pemafibrate bezafibrate ... See more keywords